Sign in →

Test Code COCN Cocaine and Metabolite Confirmation, Random, Urine

Additional Codes

Mayo Test ID
COKEU

Reporting Name

Cocaine and metabolite Conf, U

Useful For

Detecting and confirming drug abuse involving cocaine

 

This test is not intended for employment-related testing.

Method Name

Gas Chromatography Mass Spectrometry (GC-MS) Confirmation with Quantitation

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Specimen Type

Urine


Ordering Guidance


1. For situations where chain of custody is required, a Chain-of-Custody Kit (T282) is available. For chain-of-custody testing, order COKEX / Cocaine and Metabolite Confirmation, Chain of Custody, Random, Urine.

2. Additional drug panels and specific requests are available. Call 800-533-1710 or 507-266-5700.

3. If urine creatinine is required or adulteration of the sample is suspected, order ADULT / Adulterants Survey, Random, Urine.



Specimen Required


Supplies: Urine Tubes, 10 mL (T068)

Collection Container/Tube: Plastic urine container

Submission Container/Tube: 10-mL urine tube

Specimen Volume: 10 mL

Collection Instructions:

1. Collect a random urine specimen.

2. No preservative.

Additional Information:

1. No specimen substitutions.

2. STAT requests are not accepted for this test.


Specimen Minimum Volume

5 mL

Specimen Stability Information

Specimen Type Temperature Time Special Container
Urine Refrigerated (preferred) 14 days
  Frozen  14 days
  Ambient  72 hours

Reject Due To

All specimens will be evaluated at Mayo Clinic Laboratories for test suitability.

Reference Values

Negative

Positive results are reported with a quantitative gas chromatography mass spectrometry (GC-MS) result.

Cutoff concentrations:

COCAINE BY GC-MS

<50 ng/mL

 

BENZOYLECGONINE BY GC-MS

<50 ng/mL

Day(s) Performed

Monday, Wednesday, Thursday, Friday

CPT Code Information

80353

G0480 (if appropriate)

LOINC Code Information

Test ID Test Order Name Order LOINC Value
COKEU Cocaine and metabolite Conf, U 53747-2

 

Result ID Test Result Name Result LOINC Value
2922 Cocaine-by GC/MS 20519-5
2902 Benzoylecgonine-by GC/MS 16226-3
20671 Cocaine Interpretation 69050-3
28080 Chain of Custody 77202-0

Clinical Information

Cocaine is a drug of current health concern because of its proliferation among recreational drug abusers.

 

Freebase and crack increase the potential for major cocaine toxicity. Cocaine use is declining across the nation according to the National Institute of Drug Abuse.

 

Increasingly, laboratory results are disputed or there are medical/legal overtones. Therefore, physicians are finding an increased need to confirm positive results before informing or confronting the patients.

Interpretation

Reports will specifically indicate the presence or absence of cocaine and benzoylecgonine.

 

The presence of cocaine, or its major metabolite, benzoylecgonine, indicates use within the past 4 days.

 

Cocaine has a 6-hour half-life, so it will be present in urine for 1 day after last use.

 

Benzoylecgonine has a half-life of 12 hours, so it will be detected in urine up to 4 days after last use.

 

There is no correlation between concentration and pharmacologic or toxic effects.

Cautions

No significant cautionary statements

Method Description

To accommodate the need to confirm specifically the presence of cocaine in urine, Mayo Clinic Laboratories offers a single test to identify cocaine and its principal metabolite, benzoylecgonine, by using gas chromatography mass spectrometry.(Chinn DM, Crouch DJ, Peat MA, et al. Gas chromatography-chemical ionization mass spectrometry of cocaine and its metabolites in biological fluids. J Anal Toxicol 1980;4:37-42; Rosado T, Goncalves A, Margalho C, Barroso M, Gallardo E. Rapid analysis of cocaine and metabolites in urine using microextraction in packed sorbent and GC/MS. Anal Bioanal Chem. 2017;409(8):2051-2063. doi:10.1007/s00216-016-0152-2)

Report Available

2 to 5 days

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.